The role of topoisomerase IIα and HER-2 in predicting sensitivity to anthracyclines in breast cancer patients

Cancer Treatment Reviews

Volumn 35, Issue 8, 2009, Pages 662-667

  Oakman, Catherine ^a   Moretti, Erica ^a   Galardi, Francesca ^a   Santarpia, Libero ^a   Di Leo, Angelo ^a  

^a HOSPITAL OF PRATO   (Italy)

Author keywords

Anthracycline; Breast cancer; HER 2; Prediction; Topoisomerase II

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE; DNA TOPOISOMERASE IIALPHA; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; THIOTEPA; TRASTUZUMAB; UNCLASSIFIED DRUG; ANTHRACYCLINE; ANTINEOPLASTIC ANTIBIOTIC; DNA BINDING PROTEIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE II ALPHA; ERBB2 PROTEIN, HUMAN; TUMOR ANTIGEN; TUMOR MARKER;

ADJUVANT THERAPY; BREAST CANCER; CANCER RESISTANCE; CARDIOMYOPATHY; CELLULAR DISTRIBUTION; CHEMOSENSITIVITY; CHROMOSOME 17; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG MEGADOSE; GENE AMPLIFICATION; HUMAN; LEUKEMIA; LOW DRUG DOSE; OVERALL SURVIVAL; PREDICTION; PREMENOPAUSE; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; UPREGULATION; BREAST TUMOR; ENZYMOLOGY; FEMALE; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; METABOLISM; PREDICTIVE VALUE;

ANTHRACYCLINES; ANTIBIOTICS, ANTINEOPLASTIC; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PREDICTIVE VALUE OF TESTS; RECEPTOR, ERBB-2; TRANSCRIPTION, GENETIC; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 70449708986     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2009.08.006     Document Type: Review

References (47)

1. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-717.
2. Treszezamsky A.D., Kachnic L.A., Feng Z., et al. BRCA1- and BRCA2-deficient cells are sensitive to etoposide-induced DNA double-strand breaks via topoisomerase II. Cancer Res 67 (2007) 7078-7081
3. Sauter G., Lee J., Bartlett J., Slamon D., and Press M. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol 8 (2009) 1323-1333
4. Dhesy-Thind B., Pritchard K.I., Messersmith H., et al. HER-2/neu in systemic therapy for women with breast cancer: a systemic review. Breast Cancer Res Treat 109 (2008) 209-229
5. Gennari A., Sormani M.P., Pronzato P., et al. HER-2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. J Natl Cancer Inst 100 (2008) 14-20
6. DeVita V., Lawrence T., and Rosenberg S. DeVita, Hellman, and Rosenberg's cancer: principles & practice of oncology. 8th ed. (2008), Lippincott Williams and Wilkins, Philadelphia, PA
7. Isaacs R.J., Davies S.L., Sandi M.I., et al. Physiological regulation of eukaryotic topoisomerase II. Biochim Biophys Acta 1400 (1998) 121-137
8. Goswami P.C., Sheren J., Albee L.D., et al. Cell cycle-coupled variation in topoisomerase II alpha mRNA is regulated by the 3′-untranslated region. Possible role of redox sensitive protein binding in mRNA accumulation. J Biol Chem 275 (2000) 383384-383392
9. Durbecq V., Desmedt C., Paesmans M., et al. Correlation between topoisomerase-II alpha gene amplification and protein expression in HER-2 amplified breast cancer. Int J Oncol 25 (2004) 1473-1479
10. Mueller R.E., Parkes R.K., Andrulis I., et al. Amplification of the TOP2A gene does not predict high levels of topoisomerase II alpha protein in human breast tumor samples. Genes Chromosomes Cancer 39 (2004) 288-297
11. Callagy G., Pharoah P., Chin S.F., et al. Identification and validation of prognostic markers in breast cancer with complementary use of array-CGH and tissue microarrays. J Pathol 205 (2005) 388-396
12. Jarvinen T.A., Holli K., Kuukasjärvi T., et al. Predictive value of topoisomerase II alpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer. Br J Cancer 77 (1998) 2267-2273
13. Jarvinen T.A., Kononen J., Pelto-Huikko M., et al. Expression of topoisomerase II alpha is associated with rapid cell proliferation, aneuploidy, and c-erbB2 over expression in breast cancer. Am J Pathol 148 (1996) 2073-2082
14. Nakopoulou L., Lazaris A.C., Kavantzas N., et al. DNA topoisomerase II-alpha immunoreactivity as a marker of tumor aggressiveness in invasive breast cancer. Pathobiology 68 (2000) 137-143
15. Di Leo A., and Moretti E. Anthracyclines: the first generation of cytotoxic targeted agents? A possible dream. J Clin Oncol 31 (2008) 5027-5035
16. Mo Y.Y., and Beck W.T. Heterogeneous expression of DNA topoisomerase II alpha isoforms in tumor cell lines. Oncol Res 9 (1997) 193-204
17. Mirski S.E., Bielawski J.C., and Cole S.P. Identification of functional nuclear export sequences in human topoisomerase II alpha and beta. Biochem Biophys Res Commun 306 (2003) 905-911
18. Turner J.G., Engel R., Derderian J.A., et al. Human topoisomerase II alpha nuclear export is mediated by two CRM-1-dependent nuclear export signals. J Cell Sci 117 (2004) 3061-3071
19. Oloumi A., MacPhail S.H., Johnston P.J., et al. Changes in subcellular distribution of topoisomerase II alpha correlate with etoposide resistance in multicell spheroid and xenograft tumours. Cancer Res 60 (2000) 5747-5753
20. Ernst A.I., Soltermann A., Sigrist J.A., et al. Ectopic expression of human topoisomerase II alpha fragments and etoposide resistance in mammalian cells. Int J Cancer 88 (2000) 99-107
21. Jarvinen T.A., and Liu E.T. HER-2/neu and topoisomerase II alpha in breast cancer. Breast Cancer Res Treat 78 (2003) 299-311
22. Beser A.R., Tuzlali S., Guzey D., et al. HER-2, TOP2A and chromosome 17 alterations in breast cancer. Pathol Oncol Res 13 (2007) 180-185
23. Bofin A.M., Ytterhus B., and Hagmar B.M. TOP2A and HER-2 gene amplification in fine needle aspirates from breast carcinomas. Cytopathology 14 (2003) 314-319
24. Slamon DJ, Mackey J, Robert N, et al. Role of anthracycline-based therapy in the adjuvant treatment of breast cancer: efficacy analyses determined by molecular subtypes of the disease. San Antonio Breast Cancer Sympos 2007:13 [abstract].
25. O'Malley F., Chia S., Tu D., et al. Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. J Natl Cancer Inst 101 (2009) 644-650
26. Gennari A, Sormani M, Pfeffer U, et al. TOP mRNA expression in HER2 negative breast cancer. San Antonio Breast Cancer Sympos 2008:6036 [abstract].
27. McArthur HL, Tan LK, Patil S, et al. High resolution representational oligonucleotide microarray analysis (ROMA) suggests that TOPO2 and HER2 coamplification is uncommon in human breast cancer. San Antonio Breast Cancer Sympos 2009:69 [abstract].
28. Paik S., Bryant J., Park C., et al. ErbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 90 (1998) 1361-1370
29. Thor A.D., Berry D.A., Budman D.R., et al. ErbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst 90 (1998) 1346-1360
30. Di Leo A., Gancberg D., Larsimont D., et al. HER-2 amplification and topoisomerase II alpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin Cancer Res 8 (2002) 1107-1116
31. Tanner M., Isola J., Wiklund T., et al. Topoisomerase IIa gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Cancer Group Trial 9401. J Clin Oncol 24 (2006) 2428-2436
32. Paik S., Taniyama Y., and Geyer C. Anthracyclines in the treatment of HER2-negative breast cancer. J Natl Cancer Inst 100 (2008) 6-8
33. De Laurentiis M, Caputo F, Massarelli E, et al. HER2 expression and anthracycline effect: results from the Naples GUN3 randomised trial. Proc Am Assoc Cancer Res 2001:133 [abstract].
34. Pritchard K.I., Shepherd L.E., O'Malley F.P., et al. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. New Engl J Med 354 (2006) 2103-2111
35. Barlett J.M.S., Munro A.F., Cameron D.A., et al. Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trials. J Clin Oncol 26 (2008) 5027-5035
36. Slamon D, Eiermann W, Robert N, et al. BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC → T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC → TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2neu positive early breast cancer patients. San Antonio Breast Cancer Sympos 2006:52 [abstract].
37. Knoop A.S., Knudsen H., Baslev E., et al. Retrospective analysis of topoisomerase 2a amplification and deletion as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil: Danish Breast Cancer Cooperative Group. J Clin Oncol 23 (2005) 7483-7490
38. Bartlett JMS, Munro A, Dunn JA, et al. Chromosome 17 polysomy (Ch17) as a predictor of anthracycline response: emerging evidence form the UK NEAT adjuvant breast cancer trial. San Antonio Breast Cancer Sympos 2008:45 [abstract].
39. Harris L.N., Broadwater G., Abu-Khalaf M., et al. Topoisomerase IIα amplification does not predict benefit from dose-intense cyclophosphamide, doxorubicin, and fluorouracil therapy in HER2-amplified early breast cancer: results of CALGB 8541/150013. J Clin Oncol 21 (2009) 3430-3436
40. Desmedt C, Azambuja E, Larsimont D, et al. Predicting the efficacy of anthracyclines in breast cancer (BC) patients: results of the neoadjuvant TOP trial. Proc Am Soc Clin Oncol 2009:523 [abstract].
41. Burgess D., Doles J., Zender L., et al. Topoisomerase levels determine chemotherapy response in vitro and in vivo. Proc Natl Acad Sci USA 105 (2008) 9053-9058
42. Di Leo A, Isola J, Piette F, et al. A meta-analysis of phase III trials evaluating the predictive value of HER2 and topoisomerase II alpha in early breast cancer patients treated with CMF or anthracycline-based adjuvant therapy. San Antonio Breast Cancer Sympos 2008:705 [abstract].
43. Orlando L., Del Curto B., Gandini S., et al. Topoisomerase II alpha gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive HER2/neu-positive breast cancer. Breast 17 (2008) 506-511
44. .
45. Reinholz M.M., Bruzek A.K., and Visscher D.W. Breast cancer and aneusomy 17: implications for carcinogenesis and therapeutic response. Lancet Oncol 10 (2009) 267-277
46. Ejlertsen B, Jensen M-B, Nielsen KV, et al. TOP2A, TIMP-1 and responsiveness to adjuvant anthracycline containing chemotherapy in high risk breast cancer patients. San Antonio Breast Cancer Sympos 2008:36 [abstract].
47. Farmer P., Bonnefoi H., Anderle P., et al. A stroma-related gene signature predicts response to neoadjuvant chemotherapy in breast cancer. Nature Med 1 (2009) 68-74